Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + XELOX for locally advanced gastric cancer
NCT05715632Unknown
- Sponsor
- Tangdu Hospital
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab in gastric cancer (GC), sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response Rate. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05715632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715632.